BSE filing, NSE: ABCAPITAL. Summary written from the filing by ALFA Finder's alert engine.
Aditya Birla Capital Ltd: key numbers
- Share price
- ₹369.45
- Market cap
- ₹1,01,156 Cr
- Revenue (annual)
- ₹45,509 Cr
- Net profit (annual)
- ₹3,764 Cr
- P/E (TTM)
- 24.6×Sector 21.6×
- Promoter holding
- 68.82%+0.01% QoQ
- FII holding
- 8.26%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aditya Birla Capital Ltd
All →Aditya Birla Capital Debt & Borrowing
Aditya Birla Capital confirms full utilization of NCD and sub-debt issue proceeds for Q3 FY27 under Reg 52(7). No deviation from intended use was reported across 12 listed tranches.
Aditya Birla Capital Other Announcement
Aditya Birla Capital filed a quarterly Monitoring Agency Report confirming no deviation in utilizing its ₹4,000 Crore Preferential Issue proceeds. The filing covers the quarter ended 30 September 2026.
Aditya Birla Capital Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue ₹16,545 Cr (+31% y-o-y) and PAT ₹1,288 Cr (+38% y-o-y). Lending portfolio ₹2,33,930 Cr (+32%). Strategy centres on AI-led underwriting and omnichannel distribution.
Aditya Birla Capital Q2 FY27 Results: Net Profit ₹1,353 Cr, Up 40.9% YoY
Aditya Birla Capital Ltd reported revenue from operations of ₹14,003 Cr (+32.2% YoY) and net profit of ₹1,353 Cr (+40.9% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1,353 Cr · +40.9% YoY
Aditya Birla Capital Employee Stock Options
Aditya Birla Capital allotted 24,884 equity shares under its ESOP/RSU/PSU schemes on October 23, 2026. Paid-up capital increased to 27,38,00,66,370 shares of ₹10 each.
Aditya Birla Capital Debt & Borrowing
Aditya Birla Capital Limited fixed record dates for interest payments on various NCD series due in December 2026.
Other regulatory approval announcements
All →Nesco Regulatory Approval
Nesco Limited received a Commencement Certificate from BMC for Tower-2 and Hall-1 at Nesco Center, Goregaon. The company can now proceed with construction and development of the proposed projects, valid until 29 October 2027.
Grasim Industries Regulatory Approval
CCI approved subsidiary ABReN's acquisition of 100% of Solenergi Power from Shell Overseas. The approval clears a regulatory condition for the deal announced on 13 July 2026.
Vedavaag Systems Regulatory Approval
Vedavaag's WOS received IRDAI Certificate of Registration to act as Direct Life & General Insurance Broker. The group enters regulated insurance broking activity.
Hikal Regulatory Approval
Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
RNFI Services Regulatory Approval
RNFI received RBI no-objection to acquire control of Smart Payment Solutions Private Limited. Remaining tranches may proceed, but no transaction value is disclosed.